 |
|
|
|
|
|
|
 |
|
|
For further information on
inVentiv Health, please contact us. |
|
| DAVE BASSIN |
| Chief Financial Officer |
| inVentiv Health |
|
| 732.537.4800 |
|
| investor@inventivhealth.com |
|
|
|
|
|
|
|
|
|
|
|
|
| Eran Broshy -
Chairman |
|
Chief
Executive
Officer
and
Chairman |
|
|
Mr.
Broshy
is the
Chairman
and
Chief
Executive
Officer
of
inVentiv
Health,
Inc. (Nasdaq:
VTIV).
inVentiv
Health
is the
leading
provider
of
commercialization
and
complementary
services
to the
global
pharmaceutical,
life
sciences
and
biotechnology
industries,
supporting
the
needs of
over 200
unique
clients
including
all top
20
global
pharmaceutical
companies.
inVentiv
delivers
a broad
range of
customized
clinical,
sales,
marketing
and
communications
solutions
through
its
three
core
business
segments:
inVentiv
Clinical,
inVentiv
Communications
and
inVentiv
Commercial.
Mr.
Broshy
joined
inVentiv
Health
as Chief
Executive
Officer
and
Director
in June
1999,
took the
company
public
in the
fall of
1999,
and
additionally
became
Chairman
of the
Board in
June
2006. |
|
|
Mr.
Broshy
has over 21
years'
management
and
consulting
experience
within
the
healthcare
industry
and is a
widely
recognized
industry
expert
and
frequent
speaker
on
strategic
issues
in the
pharmaceutical
and
healthcare
industries.
Prior to
joining
inVentiv
he
served
as the
Partner
responsible
for the
healthcare
practice
of The
Boston
Consulting
Group (BCG)
across
the
Americas.
During
his
fourteen-year
tenure
at BCG
from
1984 to
1998,
Mr.
Broshy
consulted
widely
with
senior
executives
from a
number
of the
major
global
pharmaceutical
manufacturers,
managed
care
organizations,
and
academic
medical
centers,
and
advised
on a
range of
strategic,
organizational
and
operational
issues.
Mr.
Broshy
has also
served
as
President
and
Chief
Executive
Officer
of
Coelacanth
Corporation,
a
privately-held
biotechnology
company. |
|
|
Mr.
Broshy
currently
also
serves
as a
Director
of
Neurogen
Corporation
(Nasdaq:
NRGN), a
biotechnology
company,
and on
the
Simon
Wiesenthal
Center’s
NY
Executive
Board.
Mr.
Broshy
is a
graduate
of
Harvard
University
(M.B.A.),
Stanford
University
(M.S.),
and
Massachusetts
Institute
of
Technology
(B.S.). |
|
 Top of Page |
|
|
|
| A. Clayton Perfall - Director |
| President, Chief Executive Officer and Director of AHL Services, Inc. |
|
| A. Clayton Perfall, 46, has been a director of the Company since inVentiv's separation from Snyder Communications, Inc., in September 1999. He currently serves as Chief Executive Officer of AHL Services, Inc., a non-pharmaceutical, outsourced sales and marketing company. Prior to taking this position in October 2001, Mr. Perfall served as Chief Executive Officer of Convergence Holdings, Corp. Prior to taking this position in January 2001, Mr. Perfall served as the Chief Financial Officer and a director of Snyder Communications, Inc., from 1996 to September 2000. Prior to joining Snyder Communications, Inc., Mr. Perfall spent fifteen years with Arthur Andersen LLP. |
|
| Top of Page |
|
|
|
| Per G. H. Lofberg - Director |
| President & Chief Executive Officer, Merck Capital Ventures, LLC |
|
| Mr. Lofberg, 58, has been a director of the Company since February 2005. Mr. Lofberg brings over 31 years' pharmaceutical and healthcare industry experience to inVentiv Health. He is currently President and CEO of Merck Capital Ventures, LLC, a position that he has held since 2000. From 1993-2000, Mr. Lofberg was Chairman of Merck-Medco Managed Care, LLC, a wholly owned subsidiary of Merck & Co., Inc. and the country's largest provider of prescription drug benefit management services. Under his leadership, Merck-Medco grew from $3 billion to $23 billion in revenues. Mr. Lofberg joined Medco in 1988 as Senior Executive Vice President, a member of the Office of the President and the company's Board of Directors. Before Merck-Medco, Mr. Lofberg was a Partner at The Boston Consulting Group and oversaw the firm's worldwide healthcare practice. |
|
| Top of Page |
|
|
|
| Mark Jennings - Director |
| Managing Partner, Generation Partners |
|
| Mr. Jennings, 43, has been a director of the Company since February 2005. Mr. Jennings is Managing Partner and co-founder of Generation Partners, a $325 million private investment firm focused on providing growth capital to companies primarily in the business and information services, communications and healthcare sectors. Prior to founding Generation, Mr. Jennings was a Partner of Centre Partners, a private investment firm affiliated with Lazard Frères & Co. Mr. Jennings began his career at Goldman Sachs & Co., where he advised companies in the areas of financial strategy, public offerings, mergers & acquisitions and leveraged buyouts. Through Generation and predecessor firms, he has invested in more than 50 companies and has served as a director on 19 boards. Mr. Jennings is also The Chairman of the Board of Trustees of Post University, Inc., a 115-year-old regionally accredited University. |
|
| Top of Page |
|
|
|
| Terrell Herring - Director |
| Chief Operating Officer, inVentiv Health |
| President and Chief Executive Officer, inVentiv Commercial |
|
| Terry Herring, 42, is Chief Operating Officer, inVentiv Health and President and CEO of inVentiv Commercial, overseeing the Ventiv Pharma Teams, Ventiv Pharma Services, and Ventiv Pharma Analytics divisions of this business segment. He has more than 19 years' experience in the pharmaceutical sales industry and previously held the positions of National Business Director, Vice President and General Manager, U. S. Sales, and President and COO, Ventiv Pharma Services prior to his appointment to President and COO of the commercial business in 2005. Under Mr. Herring's leadership, inVentiv Commercial has delivered strong revenue growth and a five-fold increase in income. In October 2005, Mr. Herring was appointed to the Board of Directors of inVentiv Health, Inc., and was named Chief Executive Officer of inVentiv Commercial in February 2006. |
|
| Before joining inVentiv, Mr. Herring was the Senior National Sales Director at Noven Pharmaceuticals, where he focused on transdermal delivery and women's health marketing. He began his career at Ciba-Geigy Pharmaceuticals and Solvay Pharmaceuticals, where he held various sales management, training, development, marketing, and operations positions. |
|
| Mr. Herring graduated magna cum laude from the Citadel, Military College of South Carolina, where he earned a B.S. in Biology. He also attended Fairleigh Dickinson and Pacific Western University where he earned his M.B.A. In addition, Mr. Herring has received graduate certificates in business and international marketing from Mercer University School of Engineering and Duke University/London Business School. |
|
| Top of Page |
|
|
|
|
R. Blane Walter - Director |
| President, inVentiv Health |
|
| Mr. Walter, 36, was named President of inVentiv Health in May 2007, with responsibility
for overseeing all three divisions of the company and developing integrated solutions
to meet client needs. |
|
|
Previously he served as President and Chief Executive Officer of inVentiv Communications
following the acquisition of inChord Communications, Inc. in October 2005. Mr. Walter
joined inChord (then known as Gerbig, Snell/Weisheimer & Associates) as an Account
Manager in 1994. In 1996, he became a Partner and later purchased the company in
2000. Under his direction as Chairman and CEO, inChord became the largest privately-held
healthcare communication company in the world, working with 16 of the world's top
20 healthcare companies and serving clients around the world through a global network with offices in 13 countries. |
|
| Prior to joining inChord, Mr. Walter worked as a financial analyst in New York City
for Smith Barney in mergers and acquisitions. |
|
|
He holds a B.S. degree in marketing and finance from Boston College. |
|
| Top of Page |
|
|
|
|
Craig
Saxton,
M.D. –
Director |
| Former Executive Vice President of Pfizer's Global Research and Development Division |
|
|
Dr.
Saxton,
64, has
been a
director
of the
Company
since
December
2006.
Dr.
Saxton
brings
over 41
years of
experience
in
pharmaceutical
drug
development
to
inVentiv,
initially
as a
clinical
investigator
and
later
through
more
than 25
years
with
Pfizer
Inc.
until
his
retirement
in 2001.
During
his time
with
Pfizer,
Dr.
Saxton
worked
in a
variety
of
positions
in both
Europe
and the
USA in
the R&D
and
International
commercial
divisions. |
|
|
Throughout
the
1990’s
he was
responsible
for
Pfizer’s
worldwide
pre-clinical
and
clinical
development
operations,
a period
in which
Pfizer
enjoyed
it’s
most
successful
growth
powered
by an
unprecedented
number
of
worldwide
approvals
and
launches
of new
chemical
entity
pharmaceutical
products. |
|
|
Each of
these
numerous
approved
products
subsequently
achieved
peak
sales in
excess
of $750
million
dollars,
totaling
more
than $25
billion
in
annual
revenue
in
recent
years. |
|
|
Dr.
Saxton
is also
Chairman
of the
Board of
Neurogen
Inc. and
a
director
of
Conjuchem
Inc. |
|
| Top of Page |
|
|
|
|
|
|
